iopofosine i 131
·Code: CLR 131
iopofosine i 131: 2 clinical trials tracked.
iopofosine i 131 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about iopofosine i 131, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor
Primary endpoint: Superiority of progression free survival (PFS)
InterventionalRandomizedopen219 targetStarted 2026-12Completion 2035-01Cellectar Biosciences, Inc.
A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer
Primary endpoint: Dose Determination for CLR 125
InterventionalRandomizedopen60 targetStarted 2025-12Completion 2029-074 sites · United StatesCellectar Biosciences, Inc.